Dr. George Golumbeski

Deputy Chairman

About-us_Leadership_George-Golumbeski
  • Year of birth 1957
  • Nationality US-American
  • Place of residence Far Hills, NJ, USA
  • Initial appointment 2018
  • End of current period 2023

Professional Development

Since 2018 Business consultant in the life sciences and healthcare industries

2018 - 2019 President, Grail Inc., Menlo Park, CA, USA

2017 - 2018 Executive Vice President & Executive Advisor for Innovation, Celgene Corporation, Summit, NJ, USA

2009 - 2017 Executive Vice President, Business Development, Celgene Corporation, Summit, NJ, USA

2008 - 2009 Chief Executive Officer, Nabriva Therapeutics AG, Vienna, Austria

2002 - 2008 Vice President, Business Development, Licensing & Strategy, Novartis Oncology, Florham Park, NJ, USA

2001 - 2002 Vice President, R&D Business Development, Elan Biopharmaceuticals, San Diego, CA, USA

2000 - 2001 Senior Director, Licensing, EMD Pharmaceuticals, Durham, NC, USA

1997 - 2000 Vice President / Director, Corporate Development, Schwarz Pharma, Mequon, WI, USA

1996 - 1997 Director, Business Development, Pierce Chemical Company, Rockford, IL, USA

1991 - 1995 Technology Acquisition Manager / Group Leader, Research & Development / Group Leader, Diagnostics Research & Development, Promega Corporation, Madison, WI, USA

Education

1986 - 1991 Postdoctoral Research, Molecular biology, University of Colorado Boulder, Boulder, CO, USA

1979 - 1985 Ph.D., Genetics, University of Wisconsin-Madison, Madison, WI, USA

1975 - 1979 B.A., Biology, University of Virginia, Charlottesville, VA, USA

Memberships in Statutory Supervisory Boards and/or in Comparable Domestic or Foreign Supervisory Bodies of Commercial Enterprises Section

Carrick Therapeutics Ltd., Dublin, Ireland* Chairman of the Board of Directors

Ananke Therapeutics, Inc., Boston, MA, USA* Chairman of the Board of Directors

Sage Therapeutics, Inc., Cambridge, MA, USA (publicly listed company) Member of the Board of Directors

Shattuck Labs, Inc., Austin, TX, USA (publicly listed company) Chairman of the Board of Directors

*not publicly listed company; group mandate
As of February 2022